3 Canadian Cannabis Stocks Investors Need To Be Watching

Acreage Pharms has been very focused increasing production capacity and Phase 2 is nearly complete (can produce 4,400 kg of cannabis per year). Invictus expects Acreage Pharms to receive its sales license in the first quarter of 2018, which should be around the time that Phase 3 is complete. Acreage Pharms is focused on the cannabis oil opportunity and recently acquired extraction technologies and hired key professionals to launch the program. Acreage Pharms will apply for an oil license as soon as it receives its sales license from Health Canada.

Earlier this month, Invictus increased its ownership interest in AB Labs from 33.3% to 50%. The terms of the investment include a direct cash investment in AB Labs of $10 million, for the acquisition of adjacent land and building, and for the retrofitting costs of that existing building.

AB Venture's development permit on 100 acres of land for the Phase 1 construction is fully funded, and its license application to Health Canada is currently in-progress. Once AB Ventures receives its ACMPR license, the entire property has the potential for cannabis cultivation,

Invictus has several potential catalysts for growth and we are favorable on this aspect of the story as well as the valuation. We consider Invictus to be an acquisition target due to the funded growth initiatives, the continued execution, and the stronger balance.

1 2 3
View single page >> |

Disclosure: This report was authored by and is property of Technical420.All information and data relied upon in drafting this report is publicly available.The author believes and considers its ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.